Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 79.48% is 14% above its 5-year average of 69.80%, near the high end of its 5-year range (0.79%–105.61%).
1.05% below its 12-month average of 80.33%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 78.78%.
GROSS MARGIN
79.48%
GROSS MARGIN AVG TTM
80.33%
GROSS MARGIN AVG 3Y
74.82%
GROSS MARGIN AVG 5Y
69.80%
GROSS MARGIN AVG 10Y
42.84%
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-1.05%
CURRENT VS 3Y AVG
+6.23%
CURRENT VS 5Y AVG
+13.87%
CURRENT VS 10Y AVG
+85.55%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
40.44%
median of 787 covered companies
CURRENT VS SECTOR MEDIAN
+96.54%
vs the sector median at left
Akebia Therapeutics, Inc.
Market Cap
$237.27M
Gross Margin
79.48%
TTM Avg
80.33%
3Y Avg
74.82%
5Y Avg
69.80%
Market Cap
$236.33M
Gross Margin
68.57%
TTM Avg
73.00%
3Y Avg
80.96%
5Y Avg
81.80%
Market Cap
$237.88M
Gross Margin
-24677.94%
TTM Avg
-13289.35%
3Y Avg
-6830.59%
5Y Avg
-4553.73%
Market Cap
$240.34M
Gross Margin
53.14%
TTM Avg
76.57%
3Y Avg
72.53%
5Y Avg
61.83%
Market Cap
$240.70M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$240.38M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$242.50M
Gross Margin
N/A
TTM Avg
31.32%
3Y Avg
30.59%
5Y Avg
32.68%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Akebia Therapeutics, Inc. (AKBA) | $237.27M | 79.48% | 80.33% | 74.82% | 69.80% |
| SIGA Technologies, Inc. (SIGA)vs › | $236.33M | 68.57% | 73.00% | 80.96% | 81.80% |
| InflaRx N.V. (IFRX)vs › | $237.88M | -24677.94% | -13289.35% | -6830.59% | -4553.73% |
| High Tide Inc. (HITI)vs › | $236.81M | 25.85% | 26.57% | 27.09% | 30.11% |
| CAMP4 Therapeutics Corporation (CAMP)vs › | $240.34M | 53.14% | 76.57% | 72.53% | 61.83% |
| Invivyd, Inc. (IVVD)vs › | $236.60M | 91.35% | 93.31% | 46.66% | 31.10% |
| Nautilus Biotechnolgy, Inc. (NAUT)vs › | $240.70M | 0.00% | 0.00% | 0.00% | 0.00% |
| Galectin Therapeutics Inc. (GALT)vs › | $240.38M | 0.00% | 0.00% | 0.00% | 0.00% |
| Lifecore Biomedical, Inc. (LFCR)vs › | $242.50M | N/A | 31.32% | 30.59% | 32.68% |
| MacroGenics, Inc. (MGNX)vs › | $232.96M | 71.12% | 81.41% | 85.88% | 90.00% |
Gross Margin
79.5%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 78.78% |
| 2026-03-31 | 76.43% |
| 2025-12-31 | 78.80% |
| 2025-09-30 | 83.49% |
| 2025-06-30 | 84.12% |
| 2025-03-31 | 86.70% |
| 2024-12-31 | 56.20% |
| 2024-09-30 | 62.16% |
| 2024-06-30 | 80.99% |
| 2024-03-31 | 91.67% |
| 2023-12-31 | 66.79% |
| 2023-09-30 | 57.17% |
| 2023-06-30 | 69.34% |
| 2023-03-31 | 49.53% |
| 2022-12-31 | 105.61% |
| 2022-09-30 | 21.42% |
| 2022-06-30 | 85.28% |
| 2022-03-31 | 49.20% |
| 2021-12-31 | 45.00% |
| 2021-09-30 | 67.30% |
| 2021-06-30 | 0.79% |
| 2021-03-31 | 33.84% |
| 2020-12-31 | 52.69% |
| 2020-09-30 | 49.41% |
| 2020-06-30 | -93.71% |
| 2020-03-31 | 68.68% |
| 2019-12-31 | 85.58% |
| 2019-09-30 | 58.40% |
| 2019-06-30 | 62.63% |
| 2019-03-31 | 56.99% |
| 2018-12-31 | 87.16% |
| 2018-09-30 | -32.85% |
| 2018-06-30 | -47.39% |
| 2018-03-31 | -33.69% |
| 2017-12-31 | 21.68% |
| 2017-09-30 | -42.22% |
| 2017-06-30 | -53.40% |
| 2017-03-31 | -187.80% |
| 2016-12-31 | -2078.18% |
| 2016-09-30 | 0.00% |
| 2016-06-30 | 0.00% |
| 2016-03-31 | 0.00% |
| 2015-12-31 | 0.00% |
| 2015-09-30 | 0.00% |
| 2015-06-30 | 0.00% |
| 2015-03-31 | 0.00% |
| 2014-12-31 | 0.00% |
| 2014-09-30 | 0.00% |
| 2014-06-30 | 0.00% |
| 2014-03-31 | 0.00% |
| 2013-12-31 | 0.00% |
| 2013-09-30 | 0.00% |
| 2013-06-30 | 0.00% |
| 2013-03-31 | 0.00% |
| 2012-12-31 | 0.00% |
